The UK MND RI’s biosampling platform has now recruited 212 people living with MND, exceeding our original target of 200, marking a significant milestone in our research programme and a key step forward in our mission: to find new treatments for MND. 

Building a foundation for biomarker-driven research

Led by institute researchers across our partnership, it is collaborating with and builds on the ALS Biomarkers initiative at University College London, which focuses on integrating biomarkers into clinical practice.

Key objectives include harmonising biosampling protocols, recruiting participants across five hub sites, and comparing remote and face-to-face sampling for key biomarkers such as neurofilament light chain (NfL).

To increase participation, the team has introduced a novel remote blood-collection system that enables individuals to collect a simple finger prick sample at home and mail it to the laboratory. This innovative approach aims to make participation easier and more accessible.

Why this matters

Biological samples collected provide DNA for genomic studies, proteins for biomarker research, and other molecules critical to understanding MND. Combined with clinical data, these resources will help researchers:

  • Better understand and identify disease subtypes for personalised medicine
  • Understand factors influencing progression and outlook
  • Explore strategies to slow or prevent disease via new treatment targets

The study also aims to generate key evidence for the use of NfL in clinical practice, a biomarker strongly associated with disease severity and progression.

This work underscores the potential to improve patient care and motivates ongoing efforts in biomarker research. You can read more about the recent research on the importance of understanding biomarkers here.

 Looking ahead

This milestone strengthens the Institute’s commitment to improving understanding of MND and developing new treatments. It also highlights our vital role in uniting MND researchers and institutions from across the UK.

Future work will focus on comparing remote and in-person sampling, validating biomarker panels, and aligning biosampling with clinical and registry data.

You can read about our other blogs and news stories here or read about our research here. Also sign up to our newsletter.